Monopar Therapeutics logo

Monopar Therapeutics share price today

(MNPR)

Monopar Therapeutics share price is $22 & ₹1,884.30 as on 1 Jan 2025, 2.30 'hrs' IST

$22

-1.85

(-7.76%)

Market is closed - opens 8 PM, 02 Jan 2025

View live Monopar Therapeutics share price in Dollar and Rupees. Guide to invest in Monopar Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Monopar Therapeutics. Get details on the Indian mutual funds that are investing in Monopar Therapeutics. Get Analyst recommendations and forecasts along with all the Monopar Therapeutics's financials.

Monopar Therapeutics share price movements

  • Today's Low: $21.89
    Today's High: $24.98

    Day's Volatility :12.35%

  • 52 Weeks Low: $1.55
    52 Weeks High: $38.50

    52 Weeks Volatility :95.99%

Monopar Therapeutics Returns

PeriodMonopar Therapeutics IncIndex (Russel 2000)
3 Months
383.52%
0.0%
6 Months
511.03%
0.0%
1 Year
999.73%
0.0%
3 Years
29.41%
-21.2%

Monopar Therapeutics Key Statistics

in dollars & INR

Previous Close
$23.85
Open
$23.78
Today's High
$24.975
Today's Low
$21.8918
Market Capitalization
$134.2M
Today's Volume
$20.0K
52 Week High
$38.5
52 Week Low
$1.545
Revenue TTM
$0.0
Earnings Per Share (EPS)
$-1.98
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-102.31%

How to invest in Monopar Therapeutics from India?

It is very easy for Indian residents to invest directly in Monopar Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Monopar Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Monopar Therapeutics or MNPR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Monopar Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Monopar Therapeutics shares which would translate to 0.039 fractional shares of Monopar Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Monopar Therapeutics, in just a few clicks!

Returns in Monopar Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Monopar Therapeutics investment value today

Current value as on today

₹11,02,867

Returns

₹10,02,867

(+1K%)

Returns from Monopar Therapeutics Stock

₹10,00,000 (+1K%)

Dollar Returns

₹2,867 (+2.87%)

Indian investors sentiment towards Monopar Therapeutics

-28%

Period: Oct 3, 2024 to Jan 1, 2025. Change in 30 Days versus previous period

Search volume for Monopar Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 2, 2025. -28% less investors are searching Monopar Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Monopar Therapeutics

  • Geode Capital Management, LLC

    0.27%

  • Goss Wealth Management LLC

    0.01%

  • UBS Group AG

    0.01%

  • Wells Fargo & Co

    0.01%

Analyst Recommendation on Monopar Therapeutics

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Monopar Therapeutics(by analysts ranked 0 to 5 stars)

Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
7
Hold
1
2
3
Sell
0
0
0

Analyst Forecast on Monopar Therapeutics

What analysts predicted

Upside of 24.24%

Current:

$22.00

Target:

$27.33

Insights on Monopar Therapeutics

  • Price Movement

    In the last 3 months, MNPR stock has moved up by 353.6%
  • MNPR vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.8% return, outperforming this stock by 1.7%

Monopar Therapeutics Technicals Summary

Sell

Neutral

Buy

Monopar Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Monopar Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monopar Therapeutics Inc
-5.05%
511.03%
999.73%
29.41%
-73.86%
Regeneron Pharmaceuticals, Inc.
-4.97%
-31.12%
-22.37%
13.59%
91.62%
Biontech Se
-1.42%
42.28%
3.53%
-50.85%
155.61%
Alnylam Pharmaceuticals, Inc.
-6.56%
-6.26%
23.43%
35.31%
102.91%
Vertex Pharmaceuticals Incorporated
-11.88%
-15.14%
-1.95%
80.96%
79.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monopar Therapeutics Inc
NA
NA
NA
-1.77
-1.02
-0.53
NA
1.88
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monopar Therapeutics Inc
Buy
$134.2M
-73.86%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
91.62%
17.61
33.61%
Biontech Se
Buy
$27.3B
155.61%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
102.91%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
79.75%
32.84
-4.51%

About Monopar Therapeutics

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
Organization
Monopar Therapeutics
Employees
9
CEO
Dr. Christopher M. Starr Ph.D.
Industry
Health Technology

Management People of Monopar Therapeutics

NameTitle
Dr. Christopher M. Starr Ph.D.
Co-Founder & Independent Executive Chairman of the Board
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, CEO, President & Director
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Mr. Karthik Radhakrishnan CFA
CFO, Principal Accounting Officer & Principal Financial Officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer

Important FAQs about investing in Monopar Therapeutics from India :

What is Monopar Therapeutics share price today?

Monopar Therapeutics share price today stands at $22.00, Open: $23.78 ; Previous Close: $23.85 ; High: $24.98 ; Low: $21.89 ; 52 Week High: $38.50 ; 52 Week Low: $1.55. The stock opens at $23.78, after a previous close of $23.85. The stock reached a daily high of $24.98 and a low of $21.89, with a 52-week high of $38.50 and a 52-week low of $1.55.

Can Indians buy Monopar Therapeutics shares?

Yes, Indians can invest in the Monopar Therapeutics (MNPR) from India.

With INDmoney, you can buy Monopar Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Monopar Therapeutics at zero transaction cost.

How can I buy Monopar Therapeutics shares from India?

It is very easy to buy Monopar Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Monopar Therapeutics be purchased?

Yes, you can buy fractional shares of Monopar Therapeutics with INDmoney app.

What are the documents required to start investing in Monopar Therapeutics stocks?

To start investing in Monopar Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Monopar Therapeutics

Today’s highest price of Monopar Therapeutics (MNPR) is $24.98.

Today’s lowest price of Monopar Therapeutics (MNPR) is $21.89.

What is today's market capitalisation of Monopar Therapeutics

Today's market capitalisation of Monopar Therapeutics MNPR is 134.2M

What is the 52 Week High and Low Range of Monopar Therapeutics

  • 52 Week High

    $38.50

  • 52 Week Low

    $1.55

What are the historical returns of Monopar Therapeutics?

  • 1 Month Returns

    -5.05%

  • 3 Months Returns

    511.03%

  • 1 Year Returns

    999.73%

  • 5 Years Returns

    -73.86%

Who is the Chief Executive Officer (CEO) of Monopar Therapeutics

Dr. Christopher M. Starr Ph.D. is the current Chief Executive Officer (CEO) of Monopar Therapeutics.